Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817195 | 0.87 | SIGMAR1 (0.59) | SIGMAR1POLB | |
| SCHEMBL27406758 | 0.87 | SIGMAR1 (0.59) | SIGMAR1POLB | |
| Hydrochloric Acid SCHEMBL10662811 | 0.86 | LTA4H (0.49) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL15670332 | 0.84 | LTA4H (0.49) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL18325 | 0.81 | LTA4H (0.61) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL24350 | 0.81 | LTA4H (0.61) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL3491795 | 0.81 | LTA4H (0.61) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL23222260 | 0.80 | POLB (0.49) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL30259527 | 0.80 | POLB (0.49) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL13349604 | 0.80 | POLB (0.43) | SIGMAR1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | SIGMAR1 2317/4885CA1 721/4885CA2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.